EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer Summit 2024

 

22-24 February, Rotterdam
Close
N. Poster
Poster title
Applicant name
Status
  1-PO2 A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine Eleonora Alimenti Received Received
  1-PO8 Efficacy and safety of atezolizumab-bevacizumab for hepatocellular carcinoma in real-life clinical practice: data from a multicenter collaborative study Bernardo Stefanini Received Received
  1-PO3 Role of Nrf2 signaling in the crosstalk between Trx1 and GSNOR-redox regulators in liver cancer cells Natalia García-Villasante Received Received
  1-PO6 Characterization of ENTOSIS, a cell cannibalism process, in HEPATOCELLULAR CARCINOMA Violaine Moreau Received Received
  1-PO5 Idarubicin-infused transarterial chemoembolization (TACTida) as potential therapy for HCC-patients : Clinical and ex-vivo assessment of drug response and survival to varying IDA concentrations Jaafar Khaled Received Received
  1-PO4 Targeting endoplasmic reticulum-stress pathways : AMG-PERK and TUDCA inhibitors as potential repressors for hepatocellular carcinoma progression Jaafar Khaled Received Received
  1-PO7 a-FAtE: a new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma incorporating a-Fetoprotein, Alkaline phosphatase and Eosinophil count Federico Rossari Received Received
  2-PO4 Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variation in incidence, survival, routes to diagnosis and treatment Shahid Khan Received Received
  2-PO7 Erodosteine attenuates metabolic dysfunction-associated fatty liver disease in experimental animals: molecular pathway insight Jatin Sharma Received Received
  2-PO3 Volumetry-based assessment of post-hepatectomy liver failure Alexander Gerlach Received Received
  2-PO6 Involvment of the potassium channel ERG1 in cholangiocarcinoma Mirella Pastore Received Received
  2-PO1 Circulating hypermethylated RASSF1A as a marker of hepatocellular carcinoma in chronic HCV patients Mohamed Abdel-Samiee Received Received
  2-PO2 effect of atorvastatin together with rifaximin in the prevention of hepatocarcinogenesis generated by dioxin-type toxic Mario Álvares-Da-Silva Received Received
  2-PO8 Readability, reliability, and accuracy of publicly available large language models on liver cancer diagnosis and management Justin Tse Received Received
  2-PO5 Emerging role of oncogenic -CATENIN in EXOSOME biogenesis as a driver of IMMUNE ESCAPE in hepatocellular carcinoma Violaine Moreau Received Received
  3-PO2 Treatment of Hepatocellular Carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study Lorenzo Canova Received Received
  3-PO8 High viscoelasticity promotes the progression of hepatocellular carcinoma (HCC) in pre-cirrhotic livers Lorand Vancza Received Received
  3-PO5 Targeting hepatocellular carcinoma: evaluation of vicinal diaryl isoxazole and pyrazole derivatives with implications for oxidative stress and senescence-mediated anti-tumor mechanisms Esra Nalbat Received Received
  3-PO1 Evaluation of glycemia and diabetes as prognostic factors in advanced hepatocellular carcinoma treated with systemic therapy Antonio Acquaviva Received Received
  3-PO6 Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB) Mara Persan Received Received
  3-PO7 Better endpoints of outcome comparisons between HAIC and Sorafenib in advanced hepatocellular carcinoma: a systematic review and meta-analysis TENGFEI SI Received Received
  3-PO3 MAP17 stimulates mitochondrial activity by enhancing one-carbon metabolism, leading to the promotion of EMT in hepatocellular carcinomas (HCCs) CLÀUDIA GIL PITARCH Received Received
  3-PO4 Development of microenvironment-dependent hepatocellular carcinoma and colorectal liver metastasis spheroid culture models Elisabeth Knetemann Received Received
  4-PO3 Analytical and clinical evaluation of a novel enzyme-immunoassay for the measurement of circulating protein induced by vitamin K absence or antagonist II in patients with hepatocellular carcinoma of viral-etiology Marta Guariglia Received Received
  4-PO2 HCC incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up Gian Paolo Caviglia Received Received
  4-PO6 Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma Katharina Pomej Received Received
  4-PO5 Revolutionizing post-surgical outcome predictions: non-invasive tests and AI for hepatocellular carcinoma patients Iuliana Nenu Received Received
  4-PO8 Establishment of a national Hepatocellular carcinoma service has addressed regional inequality in access to treatments including liver transplant Ambily Tony Received Received
  4-PO4 Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells MARIA KOPSIDA Received Received
  4-PO7 The detrimental effect of metabolic risk factors on GENDER DIFFERENCES in HCC development and treatment allocation. Daniel Smith Received Received
  4-PO1 Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice Eleonora Alimenti Received Received
  5-PO6 The impact of AGE and GENDER on the SURVIVAL of patients diagnosed with HEPATOCELLULAR carcinoma Pompilia Radu Received Received
  5-PO1 Extracellular vesicles size, concentration and different miRNA expression when compared with serum in MASLD: from steatosis to hepatocellular carcinoma Mario Álvares-Da-Silva Received Received
  5-PO8 Demographic and clinical features of the patients diagnosed with hepatocellular carcinoma in Spain: Results of the III Registry of the Spanish Association for the Study of the Liver (AEEH) Maria Varela Received Received
  5-PO4 Impact of glucose homeostasis on postoperative complications after major hepatectomies Paul Krebs Received Received
  5-PO7 Prognostic value of ultra-low-pass whole genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment Miguel Sogbe Received Received
  5-PO2 Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours Ciro Celsa Received Received
  5-PO3 1-Piperidine propionic acid is effective in reducing HCC development and fatty acid accumulation in experimental liver carcinogenesis Pietro Guerra Received Received
  6-PO3 Transcriptomic landscape of epigenetic effectors in human cholangiocarcinoma Maite G Fernandez-Barrena Received Received
  6-PO1 Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab Elisabeth Amade Received Received
  6-PO8 Household income is associated with a higher likelihood of receiving curative treatment in hepatocellular carcinoma Juan Vaz Received Received
  6-PO5 Being part of surveillance programme alone improves early-stage hepatocellular carcinoma detection Adina Olaru Received Received
  6-PO2 Exploring the role of aMAP and Toronto score: beyond diagnosis to prognosis Annalisa Cespiati Received Received
  6-PO7 Pre-treatment serum N-glycans predict poor immunotherapy response and survival in Hepatocellular Carcinoma Nicky Somers Received Received
  6-PO6 Assessment of liver fibrosis with transient elastography in non-alcoholic fatty liver disease patients; a real-life experience from pakistan Lajpat Rai Received Received
  6-PO4 Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab Lorenzo Lani Received Received
  7-PO3 Role of nitric oxide in cell resistance to Sorafenib in HepG2 cell line Thaissa Horne Received Received
  7-PO2 Extrachromosomal circular DNA facilitates the crosstalk between hepatocytes and immune cells through the cGAS-STING pathway to promote immune response and HCC Lap Kwan Chan Received Received
  7-PO4 Bile extracellular vesicles hold protein biomarkers for the early diagnosis of cholangiocarcinoma in individuals with primary sclerosing cholangitis Ainhoa Lapitz Received Received
  7-PO7 Prophylaxis of variceal bleeding in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma Benedetta Stefanini Received Received
  7-PO6 Competitive Risk Analysis of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@100Hz) for Predicting de-novo HCC Occurrence in cACLD Patients: A prospective 5-Year Follow-up Study Federico Ravaioli Received Received
  7-PO1 Integrated hepatitis testing and treatment intervention among people who inject drugs: a comprehensive approach to increase linkage to care towards prevention of progression to hepatocellular carcinoma Rijimra Ande Received Received
  7-PO5 Differential Expression of MicroRNA-21 in MASLD and HCV-Related Hepatocellular Carcinoma: A Pilot Study Claudia Oliveira Received Received
  8-PO7 Do ACE inhibitors have a role in preventing drug-related proteinuria in advanced HCC patients? Bernardo Stefanini Received Received
  8-PO1 Pirfenidone promotes tumor cell elimination via increased infiltration of cytotoxic cells and by limiting fibrosis and responses of regulatory T cells in an experimental hepatocellular carcinoma model Scarlet Arceo-Orozco Received Received
  8-PO2 Aetiology of hepatocellular carcinoma and response to immunotherapy: is the the problem inherent in the classification of non-viral disease? Rusi Chen Received Received
  8-PO6 Cancer associated fibroblast plasticity and interaction with the tumour microenvironment in cholangiocarcinoma Aashreya Ravichandra Received Received
  8-PO5 Improvement of quality of care and patient satisfaction for patients with hepatocellular carcinoma via implementation of a specialist nurse a pilot study Larissa Pajancic Received Received
  8-PO3 cholangiocarcinoma patient-derived organoids: an in vitro platform for antibody-drug conjugates sensitivity testing Racha Hosni Received Received
  8-PO4 TM4SF5-NCOA3-PTEN linkage for albumin uptake and bioenergetics during HCC progression Jung Weon Lee Received Received
  9-PO6 Unveiling TIGAR SUMOylation in the metabolic response of liver cancer. Claudia M. Rejano Gordillo Received Received
  9-PO4 MiR-22 downregulation activates HIF-1A pathway and induces tumor progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma Ilaria Leoni Received Received
  9-PO7 Does AtezoBev present as a safe and efficacious treatment option for hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicentric real-world study. Leonardo Stella Received Received
  9-PO2 Investigating the immunogenetic heterogeneity in hepatocellular carcinoma Abigail Connor Received Received
  9-PO5 Novel ctDNA technology for liver cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR Dorian Pamart Received Received
  9-PO1 Usefulness of inhibiting the drug-export pump MRP3 for sensitizing cholangiocarcinoma to chemotherapy Maitane Asensio Received Received
  9-PO8 Impact of hospital stay on complications and long-term outcomes after major hepatectomies Nick Winkler Received Received
  9-PO3 Comparative analysis of subclassification models in patients with intermediate stage hepatocellular carcinoma (BCLC B) receiving systemic therapy Ielasi Luca Received Received
  10-PO3 Locoregional control of proton beam therapy for hepatocellular carcinoma with extrahepatic lymph node metastasis Takashi Iizumi Received Received
  10-PO1 Developing a data-driven framework to assess the performance and value of multi-disciplinary teams in HCC Pablo Azcue Received Received
  10-PO5 Non-viral etiology with low baseline neutrophil to lymphocyte ratio (NLR) and liver disease severity could predict clinical outcome in Atezolizumab-Bevacizumab treated Caucasian cirrhotic patients with advanced HCC Spyridon Pantzios Received Received
  10-PO8 Thrombocytopenia did not increase Radiofrequency Ablation- related bleeding risk in patients with hepatocellular carcinoma and cirrhosis Songchi Xiao Received Received
  10-PO6 Circular RNAs in hepatocellular carcinoma: the study of hsa_circ_0062682 Tadeja Rezen Received Received
  10-PO2 Impact of Body Mass Index on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab NOEMI CORNARA Received Received
  10-PO4 Histological and molecular characterization of GAN diet-induced obese mouse model of advanced fibrosing MASH with progression to HCC Monika Lewinska Received Received
  11-PO1 Differential deregulation of the metabolome during liver cancer progression and regression. Asha Balakrishnan Received Received
  11-PO8 A Novel Muti-tactic Approach to Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma using an array of Non-coding RNAs Rana Youness Received Received
  11-PO2 The presence of hepatocellular carcinoma (HCC) does not influence the rebalanced hemostasis in patients with cirrhosis Rares Craciun Received Received
  11-PO5 Imparing proliferation, survival and invasiveness of Intrahepatic Cholangiocarcinoma through a novel natural Hedgehog pathway inhibitor. Savino Paradiso Received Received
  11-PO4 Sensitization of cholangiocarcinoma to chemotherapy by -caryophyllene oxide-induced BCRP inhibition Rocio Macias Received Received
  11-PO6 Caspases compromise SLU7 and UPF1 stability and nonsense-mediated RNA decay activity during hepatocarcinogenesis Carla Rojo Received Received
  11-PO3 Risk of malignancy in patients with liver transplantation Zülal &304;stemihan Received Received
  12-PO7 Declining Hepatitis C virus-related Hepatocellular Carcinoma Mortality in the Direct-Acting Antiviral Therapy Era in the United States, From 1999 to 2021 Muhammad Ali Tariq Received Received
  12-PO2 The synergic effect of metformin with atezolizumab/bevacizumab in MASLD HCC patients: a retrospective study from ARTE multicentric Italian dataset Dalbeni Andrea Received Received
  12-PO1 High-dimensional spatial profiling of the hepatocellular carcinoma tumor microenvironment reveals spatial immune types informing immune checkpoint inhibitor therapy response Bertram Bengsch Received Received
  12-PO8 Atezolizumab-targeted liposomal doxorubicin modulates PD-L1 expression and reduces the invasive phenotype in in vitro models of hepatocellular carcinoma Ilaria Zanotto Received Received
  12-PO4 In silico electrophysiology investigation unveils cardiotoxicity Induced by Tecentric, a crucial therapeutic agent for hepatocellular carcinoma, through sodium current inhibition. Chitaranjan Mahapatra Received Received
  12-PO5 Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma Mirella Pastore Received Received
  12-PO3 Circulating vesicle microRNAs for metabolic dysfunction-associated steatotic liver disease (MASLD) staging and progression towards liver cancer Santiago Iturbe-Rey Received Received
  12-PO6 Dissociation between acute liver decompensation and radiological response in patients with hepatocellular carcinoma treated with atezolizumab-bevacizumab Martina Rosi Received Received
  13-PO4 The correlation between Interleukin-6 and the progression of chronic Hepatitis B MOHAMED SHAFI MAHBOOB ALI Received Received
  13-PO3 Combined extracellular matrix remodelling by cyclophilin inhibitor rencofilstat and immune checkpoint blockade as a potential therapy for intrahepatic cholangiocarcinoma. Ravi Jagatia Received Received
  13-PO2 Modeling cancer cells and tumor vasculature dynamics by serum biomarkers in HCC patients with different response to TKIs, TACE and TARE suggests a synergistic effect of systemic and endovascular treatments Francesco Damone Received Received
  13-PO5 Aptamers targeting HuR SUMOylation as a potential therapy for liver cancer Patricia Peña-San Felix Received Received
  13-PO6 The prognostic impact of viral and non-viral etiologies on advanced hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study Federico Rossari Received Received
  13-PO1 Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of hepatocellular carcinoma Lauriane Blukacz Received Received
  13-PO7 The role of tumor molecular profiling in patients with advanced biliary tract cancer receiving systemic treatment Giulia Tesini Received Received
  13-PO8 Biliary tract cancers (BTC): molecular profiling and matched therapy Valentina Zanuso Received Received
  14-PO1 The impact of the onset of hepatocellular carcinoma on the natural history of cirrhosis Silvia Cagnin Received Received
  14-PO3 The awareness of the link between liver cancer and hepatitis as a motivation for action results of a globally representative survey Alexandra Smith Received Received
  14-PO4 Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma Giulia Francesca Manfredi Received Received
  14-PO6 Proteomic profiling of HCC reveals the involvement of energy metabolism in treatment response Frederic Saltel Received Received
  14-PO5 Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB) Mara Persano Received Received
  14-PO8 Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma Leidy Estefanía Zapata-Pavas Received Received
  14-PO7 A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events Marco Tizzani Received Received
  15-PO2 The impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma : An analysis of a prospective cohort of liver transplant candidates Sofia El Hajji Received Received
  15-PO6 Impact of hepatitis C virus on reovirus immunotherapy for hepatocellular carcinoma Adel Samson Received Received
  15-PO3 Time-trends in cholangiocarcinoma mortality - a Danish nationwide cohort study Morten Daniel Jensen Received Received
  15-PO1 N-acetylcysteine prevents experimental hepatocellular carcinoma through modulation of the Nrf2 signaling pathway and promotion of antifibrogenic and antiproliferative effects Fernando Caloca Camarena Received Received
  15-PO5 Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma Elisa Pinto Received Received
  15-PO4 Evaluation of Overall Survival using Restricted Mean Survival Time in Advanced Biliary Tract Cancer treated with Immunotherapy: Systematic Review and Meta-analysis. Ezequiel Mauro Received Received
  15-PO7 Did we apply the BCLC classification correctly? Results from the III hepatocellular carcinoma Registry of the Spanish Association for the Study of the Liver (AEEH) MARIA VARELA Received Received
  16-PO5 Immunotherapy-tyrosine kinase inhibitor sequences for patients with advanced hepatocellular carcinoma: a single center, retrospective, comparative study Angelo Pirozzi Received Received
  16-PO3 Therapeutic potential of HuR inhibition in chronic liver disease and hepatocellular carcinoma Mickaël Jouve Received Received
  16-PO7 Exploring self-reported occupational exposures in patients with MASLD-related hepatocellular carcinoma and/or cirrhosis: a prospective pilot study Francesco Tovoli Received Received
  16-PO4 Improved multiphase liver CT scan quality with implementation of a new contrast protocol Anmol Gangi-Burton Received Received
  16-PO6 Safety profile of the Add-on combination of Regorafenib with Nivolumab after treatment with atezolizumab-bevacizumab in treated patients with hepatocellular carcinoma. Marco Sanduzzi Zamparelli Received Received
  16-PO2 Profile of Immune-Related Adverse Events and Treatment Outcomes in First-Line Immunotherapy for Hepatocellular Carcinoma Marta Fortuny Received Received
  16-PO1 Safety and efficacy of Lenvatinib in very elderly patients with unresectable hepatocellular carcinoma Silvia Camera Received Received
  17-PO1 ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments Lorenzo Canova Received Received
  17-PO7 Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease Justin Tse Received Received
  17-PO6 Testicular receptor 4 and its role in metabolic liver disease Marion Schweiger Received Received
  17-PO2 Knowledge of ultrasound LI-RADS for hepatocellular carcinoma surveillance: a comparison between two centres Anmol Gangi Received Received
  17-PO3 Targeting sirtuins with novel indole derivatives: implications for anticancer activity in hepatocellular carcinoma Deniz Kahraman Received Received
  17-PO5 Tumor-derived extracellular vesicles: ultrasensitive detection using mid-infrared resonant nanostructures Fabrizio Pizzolante Received Received
  17-PO4 The role of adenosine monophosphate-activated protein kinase pathway in sinusoidal endothelial dysfunction during the pathogenesis of metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma Mohammadjavad Sotoudeheian Received Received
  18-PO5 Decoding human Intrahepatic Cholangiocarcinoma metabolism: unveiling the impact of SLC2A3 on aggressiveness and prognosis Michela Anna Polidoro Received Received
  18-PO2 The Potential Modulatory role of Aurora Kinase A on Yes-associated protein and Glycogen synthase kinase-3 beta in Advanced Chronic Liver Disease Clarissa Joy Garcia Received Received
  18-PO1 Rare but not forgotten - comprehensive molecular and histological analysis of liver yolk sac tumor and corresponding patient-derived cell line Darko Castven Received Received
  18-PO6 High prevalence of HCC among a diverse cohort of recently deceased persons with HCV Mai Sedki Received Received
  18-PO7 Population pharmacokinetic modeling of orally administered fostroxacitabine bralpamide (fostrox, MIV-818) and its metabolite troxacitabine in a phase I/IIa liver cancer study Karin Ulrika Tunblad Received Received
  18-PO3 Brg1 suppresses DEN-induced hepatocellular carcinogenesis in mice Benedikt Kaufmann Received Received
  18-PO4 A preliminary collection of tumoral and non-tumoral patient-derived organoids for the screening of personalized therapies in hepatocellular carcinoma Elisa Monti Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
20:15
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

Liver Cancer Summit 2024

 

22-24 February, Rotterdam
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 22/02/2024 TO 22/02/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert